Schlegel U Central Nervous System Toxicity of Chemotherapy European Association of NeuroOncology Magazine 2011; 1 (1): 25-29 PDF Summary Overview
| ||||
Figure/Graphic 2a-b: MRI (a) MRI (T2-weighted) of the cervicothoracic spine showing extensive myelopathy (arrows) after intrathecal MTX 12 mg, Ara-C 30 mg + prednisolone 2.5 mg in a 31-year-old male treated for leukaemia (“triple therapy“): tetraplegia developing over 24 hours shortly after application. (b) Cerebral MRI of the same patient (FLAIR) showing affection of the pons (arrow) and medulla (arrow) resulting in coma and mechanic ventilation. Incomplete recovery with persistent paraparesis and severe bilateral hyakusis. |
Figure/Graphic 2a ![]() Figure/Graphic 2b ![]()
Figure/Graphic 2a-b: MRI
(a) MRI (T2-weighted) of the cervicothoracic spine showing extensive myelopathy (arrows) after intrathecal MTX 12 mg, Ara-C 30 mg + prednisolone 2.5 mg in a 31-year-old male treated for leukaemia (“triple therapy“): tetraplegia developing over 24 hours shortly after application. (b) Cerebral MRI of the same patient (FLAIR) showing affection of the pons (arrow) and medulla (arrow) resulting in coma and mechanic ventilation. Incomplete recovery with persistent paraparesis and severe bilateral hyakusis. |